keyword
MENU ▼
Read by QxMD icon Read
search

rituximab hepatitis b reactivation

keyword
https://www.readbyqxmd.com/read/29725560/fatal-fulminant-hepatitis-from-rituximab-induced-hepatitis-b-reactivation-in-a-patient-with-follicular-lymphoma-a-case-report-and-a-brief-review-of-literature
#1
Zarak H Khan, Kamran Ilyas, Haider Ghazanfar, Hamza H Khan, Qulsoom Hussain, Sahla Hammad, Ahmed Munir, Rizwan Asim
The objective of our study was to recognize hepatitis B reactivation as a complication of rituximab chemotherapy and to realize the importance of screening for prior Hepatitis B virus (HBV) exposure in all patients with hematologic malignancies who will receive rituximab as part of their therapy. Rituximab is a monoclonal antibody targeting CD 20 receptors on the membrane of B cells. In this case report, we described a 79-year-old man who presented to our department with nausea, fatigue, and jaundice. Two months ago, he had received the last dose of the chemotherapy regimen containing rituximab for follicular B cell lymphoma...
March 2, 2018: Curēus
https://www.readbyqxmd.com/read/29649073/safety-of-targeted-prophylaxis-strategy-in-patients-with-resolved-hepatitis-b-virus-infection-receiving-rituximab-for-immune-mediated-diseases
#2
Michele Spinicci, Giacomo Emmi, Laura Dies, Alessandro Barilaro, Gianfranco Vitiello, Jessica Mencarini, Annalisa Cavallo, Alessandro Bartoloni, Filippo Bartalesi
OBJECTIVES: Rituximab (RTX) is a monoclonal antibody that is widely used in hematologic malignancies and immune-mediated diseases (IMID) and has been associated with the risk of hepatitis B virus reactivation (HBVr). Thus, antiviral prophylaxis is recommended before RTX treatment in all patients with chronic hepatitis B virus (HBV) infection and those with resolved infection affected by onco-hematological conditions. By contrast, the correct management of HBsAg-negative/HbcAb-positive patients candidates for RTX-containing regimens for IMID is still debated, owing to few data currently available in this setting...
April 11, 2018: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29621049/hepatitis-b-virus-reactivation-in-patients-with-resolved-hepatitis-b-virus-infection-receiving-chemotherapy-or-immunosuppressive-therapy
#3
Yi-Chia Su, Pei-Chin Lin, Hsien-Chung Yu, Chih-Chien Wu
BACKGROUND: The role of antiviral prophylaxis before chemotherapy or immunosuppressive therapy to prevent hepatitis B virus (HBV) reactivation in patients with resolved HBV infection [hepatitis B surface antigen (HBsAg) negative, hepatitis B core antibody (anti-HBc) positive] is unclear. This study aimed to evaluate the efficacy of prophylactic antiviral therapy and outcomes of HBsAg-negative, anti-HBc-positive patients who received chemotherapy or immunosuppressive therapy. PATIENTS AND METHODS: We retrospectively evaluated the medical records of HBsAg-negative, anti-HBc-positive patients who underwent chemotherapy or immunosuppressive therapy from January 2013 through November 2016 at a single institute in southern Taiwan...
April 4, 2018: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29554828/management-of-hepatitis-b-reactivation-in-lymphoma-patients-on-rituximab-with-past-hepatitis-b-exposure-an-observational-study
#4
Denise Yeo, Ihtimam Hossain, Soon Thye Lim, Mohamad Farid, Miriam Tao, Richard Quek, Tiffany Tang, Alexandre Chan
Background Currently, a standardized approach to prevent and manage hepatitis B reactivation in lymphoma patients with past hepatitis exposure receiving rituximab in Singapore is lacking. This study is designed to report the current management approach and outcomes associated with hepatitis B reactivation. Objectives The primary objective was to report 6-, 12-, 24-month cumulative hepatitis B reactivation-related outcomes. Secondary objectives were to report monitoring frequencies of hepatitis B DNA and liver function tests performed in lymphoma patients with resolved hepatitis B receiving rituximab, and anti-viral prophylaxis use...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29551710/quantification-of-hbv-core-antibodies-may-help-predict-hbv-reactivation-in-patients-with-lymphoma-and-resolved-hbv-infection
#5
Hung-Chih Yang, Hsiao-Hui Tsou, Sung-Nan Pei, Cheng-Shyong Chang, Jia-Hong Chen, Ming Yao, Shyh-Jer Lin, Johnson Lin, Quan Yuan, Ningshao Xia, Tsang-Wu Liu, Pei-Jer Chen, Ann-Lii Cheng, Chiun Hsu
BACKGROUND & AIMS: Absence or low anti-HBV surface antibody (anti-HBs) is associated with an increased risk of HBV reactivation in patients with lymphoma and resolved HBV infection receiving rituximab-containing chemotherapy. Quantification of anti-HBV core antibody (anti-HBc) is a new marker associated with the natural history and treatment response of chronic HBV infection. This study investigated whether baseline anti-HBc and anti-HBs levels may better predict HBV reactivation...
March 16, 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29345413/hepatitis-b-screening-before-rituximab-therapy-a-multicentre-south-australian-study-of-adherence
#6
Samuel Al Hall, Abdul Shaikh, KailinTeh, Mahsa Tantiongco, Douglas Coghlan, Chris S Karapetis, Mohammad A Chinnaratha, Richard Woodman, Kate R Muller, Alan J Wigg
Background and Aims International guidelines recommend screening for Hepatitis B virus (HBV) infection prior to administration of rituximab, due to high risk of HBV reactivation in at risk patients. The aim of this study was to determine; (1) adherence to the South Australian (SA) protocol for HBV screening, (2) HBV prevalence in patients receiving rituximab, and (3) outcomes of patients at risk of HBV reactivation. METHODS: All patients commenced on rituximab at the 6 major SA public hospitals during a 12-month period were included in the study...
January 18, 2018: Internal Medicine Journal
https://www.readbyqxmd.com/read/29149926/drug-induced-gastrointestinal-and-hepatic-disease-associated-with-biologics-and-nonbiologic-disease-modifying-antirheumatic-drugs
#7
REVIEW
Patrick R Wood, Liron Caplan
A variety of gastrointestinal adverse drug reactions are seen in nearly all conventional antirheumatic medications, ranging from nausea to life-threatening drug-induced liver injury. Rheumatologists should be particularly familiar with hepatotoxicity associated with long-term methotrexate use, and the range of unique hepatic, biliary, and pancreatic manifestations associated with azathioprine. Hepatitis B virus reactivation is the most serious gastrointestinal disease risk associated with many biological therapies, particularly rituximab...
February 2018: Rheumatic Diseases Clinics of North America
https://www.readbyqxmd.com/read/29066086/-hbv-infection-screening-and-treatment-for-oncology-patients
#8
REVIEW
Anaïs Jaillais, Anne Herber-Mayne, Louis D'Alteroche, Alain Landau, Yacine Merrouche, Stéphane Vignot
Patients with chronic hepatitis B infection are at risk of viral reactivation when treated by immuno- or chemotherapy, with potentially serious or even fatal consequences. This article proposes an overview on screening strategies and antiviral treatment recommendations for oncology patients. We have learned in hematology that reactivations are commun with rituximab and prophylactic treatment is recommanded for any patient who has been in contact with the virus. The risk appears to be lower with cytotoxics but has been far less studied...
February 2018: Bulletin du Cancer
https://www.readbyqxmd.com/read/28898281/randomized-prospective-study-evaluating-tenofovir-disoproxil-fumarate-prophylaxis-against-hepatitis-b-virus-reactivation-in-anti-hbc-positive-patients-with-rituximab-based-regimens-to-treat-hematologic-malignancies-the-preblin-study
#9
RANDOMIZED CONTROLLED TRIAL
María Buti, María L Manzano, Rosa M Morillas, Montserrat García-Retortillo, Leticia Martín, Martín Prieto, María L Gutiérrez, Emilio Suárez, Mariano Gómez Rubio, Javier López, Pilar Castillo, Manuel Rodríguez, José M Zozaya, Miguel A Simón, Luis E Morano, José L Calleja, María Yébenes, Rafael Esteban
BACKGROUND: Hepatitis B virus (HBV) reactivation in patients with resolved HBV infection (HBsAg negative, antiHBc positive) is uncommon, but potentially fatal. The role of HBV prophylaxis in this setting is uncertain. The aim of this study was to compare the efficacy of tenofovir disoproxil fumarate (TDF) prophylaxis versus close monitoring in antiHBc-positive, HBsAg-negative patients under treatment with rituximab (RTX)-based regimens for hematologic malignancy. METHODS: PREBLIN is a phase IV, randomized, prospective, open-label, multicenter, parallel-group trial conducted in 17 hospitals throughout Spain...
2017: PloS One
https://www.readbyqxmd.com/read/28856548/risk-of-hepatitis-b-reactivation-in-hbsag-negative-hbcab-positive-patients-with-undetectable-serum-hbv-dna-after-treatment-with-rituximab-for-lymphoma-a-meta-analysis
#10
Zilin Tang, Xiaodong Li, Shunquan Wu, Yan Liu, Yan Qiao, Dongping Xu, Jin Li
BACKGROUND: Hepatitis B surface antigen (HBsAg)-negative/hepatitis B core antibody (HBcAb)-positive patients with undetectable serum hepatitis B virus (HBV) DNA have experienced and resolved hepatitis B virus (HBV) infection. Lymphoma patients with resolved HBV infection have high risk of HBV reactivation when treated with robust immunosuppressive agents, but the reported rate varies extensively between different studies. This study aims to estimate the risk of HBV reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab-containing chemotherapy for lymphoma...
September 2017: Hepatology International
https://www.readbyqxmd.com/read/28852481/infectious-complications-of-rituximab-therapy-in-renal-disease
#11
Andrew Nixon, Leanne Ogden, Alexander Woywodt, Ajay Dhaygude
Rituximab, an anti-CD20 monoclonal antibody, was originally used to treat B-cell malignancies. Its use has significantly increased in recent years, as it is now also used to treat a variety of autoimmune diseases including rheumatoid arthritis and ANCA-associated vasculitis (AAV). Initial studies suggested that the adverse effects of rituximab were minimal. Though the risk of malignancy with rituximab-based immunosuppressive regimens appears similar to that of the general population, there are now concerns regarding the risk of infectious complications...
August 2017: Clinical Kidney Journal
https://www.readbyqxmd.com/read/28838453/cholestasis-after-pediatric-liver-transplantation-recurrence-of-a-progressive-familial-intrahepatic-cholestasis-phenotype-as-a-rare-differential-diagnosis-a-case-report
#12
B Prusinskas, S Kathemann, D Pilic, B Hegen, P Küster, V Keitel, D Häussinger, R Büscher, H A Baba, P F Hoyer, E Lainka
INTRODUCTION: Nonobstructive cholestasis after pediatric liver transplantation is a common diagnostic and therapeutic dilemma. We describe a girl with neonatal cholestasis because of progressive familial intrahepatic cholestasis 2 (PFIC-2) and presence of a homozygous splice site mutation in the ABCB11 gene. Liver transplantation was performed because of end-stage liver disease at the age of 6. Cholestasis with normal gamma-glutamyl transferase (GGT) developed 8 years after liver transplantation...
September 2017: Transplantation Proceedings
https://www.readbyqxmd.com/read/28768965/reactivation-of-occult-hepatitis-b-virus-infection-27-months-after-the-end-of-chemotherapy-including-rituximab-for-malignant-lymphoma
#13
Junichi Muraishi, Michihiko Shibata, Yuichi Honma, Masaaki Hiura, Shintaro Abe, Masaru Harada
A 68-year-old man with occult hepatitis B virus (HBV) infection was diagnosed with malignant lymphoma and achieved complete remission after treatment with a chemotherapy regimen including rituximab for 5 months. Entecavir (ETV) was also used during and after chemotherapy and was ended at 14 months after chemotherapy. However, reactivation of HBV was observed in blood tests, which showed not only elevation of HBV-DNA but also HBsAg and HBeAg, at 27 months after the end of chemotherapy. After restarting ETV, the HBV-DNA levels immediately subsided...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28665891/incidence-of-hepatitis-b-viral-reactivation-after-kidney-transplantation-with-low-dose-rituximab-administration
#14
Kosuke Masutani, Kazuya Omoto, Masayoshi Okumi, Yasuhiro Okabe, Tomokazu Shimizu, Kazuhiko Tsuruya, Takanari Kitazono, Masafumi Nakamura, Hideki Ishida, Kazunari Tanabe
BACKGROUND: In hematological malignancy patients intended to receive rituximab, hepatitis B virus (HBV) serology screening, viral reactivation monitoring, are recommended. However, the effect of single-dose rituximab (RIT) on HBV reactivation in kidney transplant patients with previous HBV infection is still unclear. METHODS: In this retrospective cohort study consisting of 1294 kidney transplant patients, we identified 76 patients showing preoperative hepatitis B surface antigen-negative, hepatitis B core antibody-positive, and HBV-DNA-negative results...
January 2018: Transplantation
https://www.readbyqxmd.com/read/28648087/cost-effectiveness-of-a-hepatitis-b-virus-screening-strategy-to-prevent-reactivation-in-patients-with-hematologic-neoplasms
#15
Javier Crespo, Rafael Esteban, Covadonga Torres, Itziar Oyagüez, Miguel Ángel Casado, María Buti
INTRODUCTION: The effectiveness of a screening strategy for the detection of a hepatitis B virus (HBV) infection followed by prophylaxis in order to prevent HBV reactivation was assessed in patients with hematologic neoplasms. MATERIAL AND METHODS: A decision tree was developed to compare the cost and effectiveness (prevented reactivations) over an 18 month period of a screening strategy prior to chemotherapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) with a non-screening approach...
June 26, 2017: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/28633752/rituximab-administration-in-a-patient-with-pemphigus-vulgaris-following-reactivation-of-occult-hepatitis-b-virus-infection
#16
Soheil Tavakolpour, Tahereh Soori, Pedram Noormohammadpour, Kamran Balighi, Hamidreza Mahmoudi, Maryam Daneshpazhooh
Immunosuppressive drugs are the milestone of treatment of autoimmune diseases, but they can lead to serious complications, including hepatitis B virus reactivation in HBV carriers as well as in patients with occult HBV infection (OBI). A 36-year-old man with OBI was diagnosed with pemphigus vulgaris. He was prescribed prednisolone and his hepatitis B surface antigen turned positive. Viral replication was successfully controlled by lamivudine and adefovir. Mycophenolate mofetil and intravenous immunoglobulin  were not effective in controlling the pemphigus vulgaris...
June 20, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/28566622/factorial-analysis-of-hepatitis-b-virus-reactivation-induced-hepatitis-b-using-jader
#17
Ayako Hara, Kazuaki Matsumoto, Yuta Yokoyama, Junko Kizu
Hepatitis B caused by chemotherapy- and immunosuppression-associated hepatitis B virus reactivation is likely to become fulminant, and a high mortality rate has been reported. In this study, using the Japanese adverse drug event report database (JADER), factorial analysis of patients who developed hepatitis B as an adverse event was performed. The number of reported cases of hepatitis B during the survey period was 781 and 185 of them (24%) died. Rituximab and prednisolone were administered to many cases (233, 216 cases, respectively), and the reporting odds ratios were high (65...
2017: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/28414152/rituximab-for-immunologic-renal-disease-what-the-nephrologist-needs-to-know
#18
REVIEW
Andreas Kronbichler, Martin Windpessl, Herwig Pieringer, David R W Jayne
Rituximab (RTX), a chimeric, monoclonal anti-CD20 antibody, is increasingly used in immune-mediated renal diseases. While licensed in the induction treatment of ANCA-associated vasculitis, it represents one of the most commonly prescribed off-label drugs. Much of the information regarding its safety has been drawn from experience in hematology and rheumatology. Ample evidence illustrates the safety of RTX, however, rare but serious adverse events have emerged that include progressive multifocal leucoencephalopathy and hepatitis B reactivation...
June 2017: Autoimmunity Reviews
https://www.readbyqxmd.com/read/28375829/incidence-and-clinical-characteristics-of-hepatitis-b-virus-reactivation-in-hbsag-negative-hbcab-positive-patients-receiving-rituximab-for-rheumatoid-arthritis
#19
REVIEW
Ya-Chih Tien, Hsu-Heng Yen, Ying-Ming Chiu
OBJECTIVES: To analyse the incidence, clinical characteristics, and prognosis of patients with rheumatoid arthritis (RA) and hepatitis B virus (HBV) surface antigen negative/core antibody positive serostatus (HBsAg-/HBcAb+), who underwent rituximab therapy and developed HBV reactivation. METHODS: Medical records of RA patients with different HBV serostatus who received rituximab from January 2000 through January 2015 were reviewed. Case notes of four HBsAg-/HBcAb+ patients with RA who had HBV reactivation during treatment with rituximab were excerpted and summarised...
September 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28353614/using-health-system-wide-data-to-understand-hepatitis-b-virus-prophylaxis-and-reactivation-outcomes-in-patients-receiving-rituximab
#20
Gabriela Schmajuk, Chris Tonner, Laura Trupin, Jing Li, Urmimala Sarkar, Dana Ludwig, Stephen Shiboski, Marina Sirota, R Adams Dudley, Sara Murray, Jinoos Yazdany
Hepatitis B virus (HBV) reactivation in the setting of rituximab use is a potentially fatal but preventable safety event. The rate of HBV screening and proportion of patients at risk who receive antiviral prophylaxis in patients initiating rituximab is unknown.We analyzed electronic health record (EHR) data from 2 health systems, a university center and a safety net health system, including diagnosis grouper codes, problem lists, medications, laboratory results, procedures codes, clinical encounter notes, and scanned documents...
March 2017: Medicine (Baltimore)
keyword
keyword
110035
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"